IMTX – Immatics N.V
IMTX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
4.5
Margin Of Safety %
Put/Call OI Ratio
0.39
EPS Next Q Diff
0.01
EPS Last/This Y
-0.05
EPS This/Next Y
Price
9.63
Target Price
17.65
Analyst Recom
1
Performance Q
-13.38
Upside
-365.4%
Beta
1.33
Ticker: IMTX
19 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | IMTX | 9.23 | 3.88 | 15.50 | 1683 |
| 2026-07-14 | IMTX | 9.34 | 3.97 | 0.67 | 1714 |
| 2026-07-15 | IMTX | 9.46 | 3.97 | 3.33 | 1716 |
| 2026-07-16 | IMTX | 9.4 | 4.00 | 4.00 | 1726 |
| 2026-07-17 | IMTX | 9.61 | 4.14 | 1.30 | 1779 |
| 2026-07-20 | IMTX | 9.21 | 0.39 | 0.00 | 318 |
| 2026-07-21 | IMTX | 9.39 | 0.33 | 0.00 | 356 |
| 2026-07-22 | IMTX | 9.18 | 0.33 | 0.00 | 356 |
| 2026-07-23 | IMTX | 9.28 | 0.33 | 0.00 | 356 |
| 2026-07-24 | IMTX | 9.09 | 0.33 | 0.00 | 356 |
| 2026-07-27 | IMTX | 8.63 | 0.33 | 0.00 | 356 |
| 2026-07-28 | IMTX | 8.74 | 0.33 | 0.00 | 356 |
| 2026-07-29 | IMTX | 9.01 | 0.33 | 999.99 | 357 |
| 2026-07-30 | IMTX | 9.2 | 0.34 | 0.00 | 358 |
| 2026-07-31 | IMTX | 8.66 | 0.33 | 999.99 | 359 |
| 2026-08-03 | IMTX | 9.02 | 0.34 | 999.99 | 360 |
| 2026-08-04 | IMTX | 9.35 | 0.34 | 999.99 | 360 |
| 2026-08-05 | IMTX | 9.78 | 0.34 | 999.99 | 360 |
| 2026-08-07 | IMTX | 9.64 | 0.39 | 0.00 | 373 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
19 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | IMTX | 9.23 | 28.7 | - | -1.94 |
| 2026-07-14 | IMTX | 9.35 | 28.7 | - | -1.94 |
| 2026-07-15 | IMTX | 9.46 | 28.7 | - | -1.94 |
| 2026-07-16 | IMTX | 9.41 | 28.7 | - | -1.94 |
| 2026-07-17 | IMTX | 9.63 | 28.7 | - | -1.94 |
| 2026-07-20 | IMTX | 9.24 | 28.7 | - | -1.94 |
| 2026-07-21 | IMTX | 9.38 | 28.7 | - | -1.94 |
| 2026-07-22 | IMTX | 9.17 | 28.7 | - | -1.94 |
| 2026-07-23 | IMTX | 9.29 | 28.7 | - | -1.94 |
| 2026-07-24 | IMTX | 9.09 | 28.7 | - | -1.94 |
| 2026-07-27 | IMTX | 8.62 | 28.7 | - | -1.94 |
| 2026-07-28 | IMTX | 8.73 | 28.7 | - | -1.94 |
| 2026-07-29 | IMTX | 9.00 | 28.7 | - | -1.94 |
| 2026-07-30 | IMTX | 9.21 | 28.7 | - | -1.94 |
| 2026-07-31 | IMTX | 8.67 | 28.7 | - | -1.94 |
| 2026-08-03 | IMTX | 9.02 | 28.7 | - | -1.94 |
| 2026-08-04 | IMTX | 9.02 | 28.7 | - | -1.94 |
| 2026-08-05 | IMTX | 9.78 | 28.7 | - | -1.94 |
| 2026-08-06 | IMTX | 9.42 | 28.7 | - | -1.94 |
| 2026-08-07 | IMTX | 9.63 | 29.8 | - | -1.90 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | IMTX | 0.00 | 5.33 | 4.82 |
| 2026-07-14 | IMTX | 0.00 | 5.33 | 4.82 |
| 2026-07-15 | IMTX | 0.00 | 5.33 | 4.82 |
| 2026-07-16 | IMTX | 0.00 | 5.33 | 4.82 |
| 2026-07-17 | IMTX | 0.00 | 5.33 | 4.82 |
| 2026-07-20 | IMTX | 0.00 | 5.22 | 4.82 |
| 2026-07-21 | IMTX | 0.00 | 5.22 | 4.82 |
| 2026-07-22 | IMTX | 0.00 | 5.22 | 4.82 |
| 2026-07-23 | IMTX | 0.00 | 5.22 | 4.82 |
| 2026-07-24 | IMTX | 0.00 | 5.22 | 4.82 |
| 2026-07-27 | IMTX | 0.00 | 5.18 | 4.50 |
| 2026-07-28 | IMTX | 0.00 | 5.18 | 4.50 |
| 2026-07-29 | IMTX | 0.00 | 5.18 | 4.50 |
| 2026-07-30 | IMTX | 0.00 | 5.18 | 4.50 |
| 2026-07-31 | IMTX | 0.00 | 5.18 | 4.50 |
| 2026-08-03 | IMTX | 0.00 | -0.81 | 4.50 |
| 2026-08-04 | IMTX | 0.00 | -0.81 | 4.50 |
| 2026-08-05 | IMTX | 0.00 | -0.81 | 4.50 |
| 2026-08-06 | IMTX | 0.00 | -0.81 | 4.50 |
| 2026-08-07 | IMTX | 0.00 | -0.81 | 4.50 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.5
Avg. EPS Est. Current Quarter
-0.48
Avg. EPS Est. Next Quarter
-0.49
Insider Transactions
Institutional Transactions
-0.81
Beta
1.33
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
11
Fair Value
Quality Score
29
Growth Score
32
Sentiment Score
91
Actual DrawDown %
40.9
Max Drawdown 5-Year %
-77.4
Target Price
17.65
P/E
Forward P/E
PEG
P/S
29.86
P/B
2.51
P/Free Cash Flow
EPS
-1.97
Average EPS Est. Cur. Y
-1.9
EPS Next Y. (Est.)
-1.9
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-572.25
Relative Volume
0.61
Return on Equity vs Sector %
-74.4
Return on Equity vs Industry %
-58.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
◆
IMTX
Healthcare
$9.65
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
2/20
Pullback
11/25
Volume
9/15
Valuation
10/20
TP/AR
2/10
Options
7/10
RSI
53.4
Range 1M
51.7%
Sup Dist
4.2%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
2/25
Growth
4/30
Estimates
0/20
Inst/Vol
1/15
Options
8/10
EPS Yr
-4.8%
EPS NY
-0.1%
52W%
61.5%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+82.9% upside
Quality
2/30
Valuation
14/30
Growth
0/25
Stability
7/10
LT Trend
0/5
Upside
+82.9%
Quality
29
Click a card to see score breakdown
Full Analysis →
IMTX — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 678
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX
Latest News
—
Caricamento notizie per IMTX…
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading